Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

globus medical inc. - GMED

GMED

Close Chg Chg %
87.72 0.19 0.21%

Closed Market

87.91

+0.19 (0.21%)

Volume: 1.06M

Last Updated:

Apr 2, 2026, 3:59 PM EDT

Trade Now

Company Overview: globus medical inc. - GMED

GMED Key Data

Open

$86.14

 Day Range

84.98 - 90.43

52 Week Range

51.79 - 101.40

 Market Cap

$11.87B

Shares Outstanding

135.06M

 Public Float

111.82M

Beta

1.09

 Rev. Per Employee

N/A

P/E Ratio

22.40

 EPS

$3.98

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.00M

  

GMED Performance

1 Week
 
 4.94%
 
1 Month
 
 0.94%
 
3 Months
 
 0.71%
 
1 Year
 
 27.73%
 
5 Years
 
 42.15%
 

GMED Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 16
Full Ratings ➔

About globus medical inc. - GMED

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. It engages in developing products that promote healing in patients with musculoskeletal disorders. The firm classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in 2003 and is headquartered in Audubon, PA.

GMED At a Glance

Globus Medical, Inc.
2560 General Armistead Avenue
Audubon, Pennsylvania 19403-5214
Phone 1-610-930-1800 Revenue 2.94B
Industry Medical Specialties Net Income 537.87M
Sector Health Technology 2025 Sales Growth 16.654%
Fiscal Year-end 12 / 2026 Employees 6,000
View SEC Filings

GMED Valuation

P/E Current 22.358
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 22.248
Price to Sales Ratio 4.072
Price to Book Ratio 2.578
Price to Cash Flow Ratio 15.88
Enterprise Value to EBITDA 14.089
Enterprise Value to Sales 3.923
Total Debt to Enterprise Value 0.01

GMED Efficiency

Revenue/Employee 489,821.833
Income Per Employee 89,644.667
Receivables Turnover 3.952
Total Asset Turnover 0.557

GMED Liquidity

Current Ratio 4.264
Quick Ratio 2.741
Cash Ratio 1.118

GMED Profitability

Gross Margin 63.388
Operating Margin 18.40
Pretax Margin 20.588
Net Margin 18.301
Return on Assets 10.192
Return on Equity 12.293
Return on Total Capital 11.462
Return on Invested Capital 12.034

GMED Capital Structure

Total Debt to Total Equity 2.612
Total Debt to Total Capital 2.545
Total Debt to Total Assets 2.252
Long-Term Debt to Equity 2.282
Long-Term Debt to Total Capital 2.224
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Globus Medical Inc. - GMED

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.02B 1.57B 2.52B 2.94B
Sales Growth
+6.76% +53.34% +60.62% +16.65%
Cost of Goods Sold (COGS) incl D&A
281.46M 599.21M 1.15B 1.08B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
68.25M 144.73M 254.02M 277.48M
Depreciation
50.52M 93.70M 134.65M 159.29M
Amortization of Intangibles
17.73M 51.03M 119.37M 118.19M
COGS Growth
+9.20% +112.89% +92.73% -6.83%
Gross Income
741.38M 969.27M 1.36B 1.86B
Gross Income Growth
+5.86% +30.74% +40.78% +36.53%
Gross Profit Margin
+72.48% +61.80% +54.16% +63.39%
2022 2023 2024 2025 5-year trend
SG&A Expense
504.98M 767.42M 1.13B 1.32B
Research & Development
72.86M 124.01M 151.14M 146.94M
Other SG&A
432.12M 643.41M 981.05M 1.18B
SGA Growth
+7.17% +51.97% +47.53% +16.78%
Other Operating Expense
- - - -
-
Unusual Expense
8.45M 68.71M 66.32M 58.52M
EBIT after Unusual Expense
227.95M 133.14M 165.99M 482.25M
Non Operating Income/Expense
15.07M 32.25M (41.08M) 122.82M
Non-Operating Interest Income
- 14.23M 20.13M 7.14M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 4.19M
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - 4.19M
-
Interest Capitalized
- - - -
-
Pretax Income
243.02M 165.39M 120.72M 605.07M
Pretax Income Growth
+34.71% -31.94% -27.01% +401.21%
Pretax Margin
+23.76% +10.54% +4.79% +20.59%
Income Tax
52.85M 42.52M 17.74M 67.20M
Income Tax - Current - Domestic
73.33M 96.69M 138.42M 36.93M
Income Tax - Current - Foreign
1.84M 4.08M 13.36M 9.85M
Income Tax - Deferred - Domestic
(19.57M) (52.64M) (117.97M) 7.17M
Income Tax - Deferred - Foreign
(2.76M) (5.61M) (16.07M) 13.26M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
190.17M 122.87M 102.98M 537.87M
Minority Interest Expense
- - - -
-
Net Income
190.17M 122.87M 102.98M 537.87M
Net Income Growth
+27.47% -35.39% -16.19% +422.28%
Net Margin Growth
+18.59% +7.83% +4.09% +18.30%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
190.17M 122.87M 102.98M 537.87M
Preferred Dividends
- - - -
-
Net Income Available to Common
190.17M 122.87M 102.98M 537.87M
EPS (Basic)
1.8928 1.0865 0.7588 3.9779
EPS (Basic) Growth
+27.81% -42.60% -30.16% +424.24%
Basic Shares Outstanding
100.47M 113.09M 135.73M 135.22M
EPS (Diluted)
1.8527 1.0719 0.747 3.9244
EPS (Diluted) Growth
+28.68% -42.14% -30.31% +425.35%
Diluted Shares Outstanding
102.64M 114.63M 137.86M 137.06M
EBITDA
304.65M 346.58M 486.34M 818.24M
EBITDA Growth
+1.88% +13.76% +40.32% +68.25%
EBITDA Margin
+29.78% +22.10% +19.30% +27.84%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 110.083
Number of Ratings 16 Current Quarters Estimate 1.058
FY Report Date 06 / 2026 Current Year's Estimate 4.471
Last Quarter’s Earnings 0.92 Median PE on CY Estimate N/A
Year Ago Earnings 3.98 Next Fiscal Year Estimate 4.956
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 14 14 14
Mean Estimate 1.06 1.16 4.47 4.96
High Estimates 1.13 1.27 4.56 5.12
Low Estimate 0.97 1.10 4.45 4.83
Coefficient of Variance 4.23 4.23 0.74 1.72

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 10 10
OVERWEIGHT 1 1 1
HOLD 5 5 5
UNDERWEIGHT 0 0 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Globus Medical Inc. - GMED

Date Name Shares Transaction Value
Nov 17, 2025 Stephen T. Zarrilli Director 25,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $44.14 per share 1,103,500.00
Nov 17, 2025 Stephen T. Zarrilli Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $84.29 per share 0.00
Nov 17, 2025 Stephen T. Zarrilli Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 17, 2025 David D. Davidar Director 541,275 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $25.52 per share 13,813,338.00
Nov 17, 2025 David D. Davidar Director 516,275 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $86 per share 44,399,650.00
Nov 17, 2025 David D. Davidar Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Globus Medical Inc. in the News